Embedded Files
Evolution of respiratory viruses
Acute respiratory infections are caused by a plethora of RNA viruses, including influenza, coronavirus and parainfluenza. We are interested in tracking the underlying molecular processes that interact to shape virus evolution and population dynamics.
Field surveillance and characterization of zoonotic pathogens across Asia
A zoonotic disease is a disease that jumps from an animal host to humans. Since 2010, we have established animal disease surveillance programs across Asia, including Cambodia, Kazakhstan, the Philippines, Singapore and Tajikistan.
We utilize a One Health approach to understand infectious disease dynamics and spillover in primary and incidental hosts. We collect samples from animals that are known sources of human pathogens (e.g. bats, camels, rodents) and develop high-throughput assays to identify and characterise new & emerging pathogens (e.g. astrovirus, coronavirus, influenza virus, filovirus, paramyxoviruses). We also provide fieldwork and bioinformatics training to our collaborative partners.
Metagenomic surveillance of swine influenza A viruses
Influenza pandemics cause significant mortality in humans and are initiated by animal viruses. Swine are mixing vessel that play a crucial role in influenza ecology and transmission. Through metagenomic surveillance, we explore the genetic diversity of swine influenza A viruses in Asia (in collaboration with institutional partners in Cambodia and London).
Understanding the molecular determinants of virus phenotype
Most RNA viruses mutate rapidly and generate genetic variants through time. Advantageous mutations can lead to continued circulation of the virus. We utilize reverse genetics approaches to study the gene mutations that may impact virus phenotype and fitness.
Development of anti-viral agents
Respiratory infections can cause severe lower respiratory tract illnesses in all age groups, but especially in infants, young children, the elderly, immunocompromised patients, and people with chronic medical conditions. We are engaged in developing antiviral agents for combating viral infections and/or preventing severe disease outcome.
Page updated
Google Sites
Report abuse